<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <schemaVersion>X0202</schemaVersion>
<headerData>
    <submissionType>SCHEDULE 13D</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0002132998</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Stock, par value $0.001 per share</securitiesClassTitle>
      <dateOfEvent>04/22/2026</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001310488</issuerCIK>
        <issuerCusips>
          <issuerCusipNumber>09064C206</issuerCusipNumber>
        </issuerCusips>
        <issuerName>BIOFORCE NANOSCIENCES HOLDINGS, INC.</issuerName>
        <address>
          <com:street1>2020 GENERAL BOOTH BLVD</com:street1>
          <com:street2>SUITE 230</com:street2>
          <com:city>VIRGINIA BEACH</com:city>
          <com:stateOrCountry>VA</com:stateOrCountry>
          <com:zipCode>23454</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Richard Kaiser</personName>
          <personPhoneNum>7573066090</personPhoneNum>
          <personAddress>
            <com:street1>2020 General Booth Blvd., Ste. 230</com:street1>
            <com:city>Virginia Beach</com:city>
            <com:stateOrCountry>VA</com:stateOrCountry>
            <com:zipCode>23454</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0002132998</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Nexus Capital Investments, Inc.</reportingPersonName>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>WY</citizenshipOrOrganization>
        <soleVotingPower>26700000.00</soleVotingPower>
        <sharedVotingPower>26700000.00</sharedVotingPower>
        <soleDispositivePower>26700000.00</soleDispositivePower>
        <sharedDispositivePower>26700000.00</sharedDispositivePower>
        <aggregateAmountOwned>26700000.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>79.6</percentOfClass>
        <typeOfReportingPerson>CO</typeOfReportingPerson>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common Stock, par value $0.001 per share</securityTitle>
        <issuerName>BIOFORCE NANOSCIENCES HOLDINGS, INC.</issuerName>
        <issuerPrincipalAddress>
          <com:street1>2020 GENERAL BOOTH BLVD</com:street1>
          <com:street2>SUITE 230</com:street2>
          <com:city>VIRGINIA BEACH</com:city>
          <com:stateOrCountry>VA</com:stateOrCountry>
          <com:zipCode>23454</com:zipCode>
        </issuerPrincipalAddress>
      </item1>
      <item2>
        <filingPersonName>Gretchen Privett, President and Secretary, Nexus Capital Investments, Inc., a Wyoming Corporation.</filingPersonName>
        <principalBusinessAddress>125 Old Monroe Road, Athens, GA, 30606</principalBusinessAddress>
        <principalJob>Nexus Capital Investments, Inc., President and Secretary, 125 Old Monroe Road, Athens, GA, 30606</principalJob>
        <hasBeenConvicted>NONE</hasBeenConvicted>
        <convictionDescription>NONE</convictionDescription>
        <citizenship>USA</citizenship>
      </item2>
      <item3>
        <fundsSource>The Reporting entity acquired the 26,700,000 shares of common stock of BFNH in a private transaction for the purchase price of $400,000, and such funds were obtained through operational working capital.</fundsSource>
      </item3>
      <item4>
        <transactionPurpose>(a) N/A
(b) BFNH and the Reporting Entity reserve the right to engage in the acquisition of other entities in the form of a merger or acquisition in the future;
(c) BFNH and the Reporting Entity reserve the right to engage in the sale or transfer of a material amount of assets in the future;
(d) No changes are forthcoming but the Conpany the reserves the right to change the management, the board and their terms in the future;
(e) BFNH reserves the right to change the capital structure of the Company in the future.
(f) N/A
(g)N/A
(h)N/A
(i) N/A
(jj) N/A
</transactionPurpose>
      </item4>
      <item5>
        <percentageOfClassSecurities>26,700,000 is approximately 79.6% based on 33,549,005 shares of common stock outstanding as reported in BFNH's June 30, 2026 Form 10Q.</percentageOfClassSecurities>
        <numberOfShares>26,700,000</numberOfShares>
        <transactionDesc>Except as otherwise disclosed herein, during the past 60 days the Reporting Persons has not effected trades in the shares of common stock of the Issuer.</transactionDesc>
        <listOfShareholders>No other persons has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares.</listOfShareholders>
        <date5PercentOwnership>N/A</date5PercentOwnership>
      </item5>
      <item6>
        <contractDescription>Except for the transactions described in this Schedule 13D, to the knowledge of the Reporting Persons, as of the date hereof, there are no contracts, arrangements, understanding or relationships (legal or otherwise) among the persons named in Item 2 hereof and between such persons or any other persons with respect to any securities of the Issuer.  </contractDescription>
      </item6>
      <item7>
        <filedExhibits>None</filedExhibits>
      </item7>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Nexus Capital Investments, Inc.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Gretchen Privett</signature>
          <title>Authorized Officer</title>
          <date>09/04/2026</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>
</edgarSubmission>
